UPDATE: COVID-19 Vaccines Rollout

WHO Member States information Session

4 MARCH 2021
State of Vaccines (at 4 Mar 2021)

- **86 days** since 1\textsuperscript{st} country started vaccinating\textsuperscript{1}; **67 days** since EU started; **3 days** since first use of COVAX doses\textsuperscript{2}

- **271 million doses** administered:
  - \(~79\%\) in 10 countries
  - 9 different vaccines (3 platforms)\textsuperscript{3}

- Started in **115 economies**: 
  - incl. 65 HICs, 30 UMICs, 19 LMICs and 1 LIC

- **COVAX has delivered doses to 15 countries**: 
  - 2 LMICs have started campaigns thanks to COVAX doses
  - In total, **10.5 million COVAX doses delivered**

\textsuperscript{1} Dec. 8, 2020 in the UK (Pfizer) \hspace{0.5cm} \textsuperscript{2} March 1 in Ghana and Côte d'Ivoire \hspace{0.5cm} \textsuperscript{3} Pfizer, Moderna, Gamaleya, Sinovac, Sinopharm, SII, Bharat Biotech, AZ

Sources: World Health Organization, Our World in Data; Bloomberg
15 countries in 4 regions have received first COVAX vaccine doses

3 March 2021
SUDAN BECOMES 15TH COUNTRY TO RECEIVE COVAX VACCINES

In total, > 10 million COVAX doses delivered in just over a week

15 countries in 4 regions already received COVAX doses
- Sudan
- DRC
- Kenya
- Senegal
- Lesotho
- Nigeria
- Ghana
- Angola
- Cambodia
- South Korea
- Colombia
- Rwanda
- The Gambia
- Côte d'Ivoire
- India

1. Vaccinations have started
SOURCE: GAVI
First round allocation for Feb-May doses published

THE COVAX FACILITY

FIRST ROUND OF ALLOCATION: ASTRA ZENECA/OXFORD VACCINE (manufactured by AstraZeneca & licensed and manufactured by Serum Institute of India)
Feb-May 2021 - last updated 2 March 2021

Introduction

Following from the publication of an interim distribution forecast, and based on current knowledge of supply availability, this first round of allocations provides information on provision of doses of the AstraZeneca/AZ/Oxford vaccine to COVAX Facility participants, through May 2021.

This first round allocation outlines delivery of 237 million doses of the AZ/Oxford vaccine – manufactured by AstraZeneca (AZ) & licensed and manufactured by Serum Institute of India (SII/AZ) – to 142 Facility participants.


The next allocation round will be the Pfizer Q2 doses
### Update on early doses

Overall, COVAX will serve 66 participants with these early ("February") doses, at least 50 of which will be receiving their 1\textsuperscript{st} COVID-19 vaccines.

<table>
<thead>
<tr>
<th>Participant groups</th>
<th>Number of Countries/ Economies</th>
<th>First POs Volume</th>
<th>First shipments</th>
<th>Countries / economies reached</th>
<th>Doses delivered</th>
</tr>
</thead>
<tbody>
<tr>
<td>First POs placed / in process</td>
<td>46</td>
<td>26 M doses</td>
<td>Feb 23</td>
<td>12</td>
<td>10.2 M</td>
</tr>
<tr>
<td>First POs placed</td>
<td>20</td>
<td>4 M doses</td>
<td>Expected this week</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>First wave participants</td>
<td>18</td>
<td>1.2 M doses</td>
<td>Feb 26</td>
<td>3</td>
<td>0.3 M</td>
</tr>
</tbody>
</table>
Public COVAX roll-out dashboard resources

1. Gavi for deliveries
   
   https://www.gavi.org/live/covax-vaccine-roll-out

2. UNICEF for planned shipments and POs
   
   https://www.unicef.org/supply/covid-19-vaccine-market-dashboard
COVAX Deliveries – key bottlenecks at 4 Mar

**International Level**
- Emergency Use Listing
- Advance Purchase Agreement (APA)
- Volume Confirmation
- Supply Agreement
- Allocation Plan

**National Level**
- National Vaccine Deployment Plan
- Indemnification Agreement
- Regulatory Authorization
- Readiness validation
- Import License

**Vaccine/Producer specific**

- **World Health Organization**
- **UNICEF**

- **Purchase Orders**
  - Export License*
  - Labelling/Packaging (& Production)
  - Shipping

- **In-country clearance**

* Only SII
Addressing the challenges to further accelerate roll-out of COVAX Facility vaccines

1. Each country needs to submit for each product a **signed I&L agreement** and a **Regulatory Authorization**

2. Ensure timely **export licenses for COVAX** (ideally waivers)

3. Prepare in-country use of vaccines by **costing¹, securing resources and preparing / launching Vx campaigns**

4. Encourage manufacturers to **rapidly provide data for EUL/PQ & SAGE²**

5. All Member States allow manufacturers to **prioritize COVAX commitments**

---

¹ Using available tools such as the CVIC tool
² WHO PQ/EUL pipeline